We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

223 hedge funds and large institutions have $5.88B invested in Neurocrine Biosciences in 2017 Q3 according to their latest regulatory filings, with 33 funds opening new positions, 98 increasing their positions, 51 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 98 | Existing positions reduced: 51

61% more call options, than puts

Call options by funds: $37.3M | Put options by funds: $23.2M

35% more capital invested

Capital invested by funds: $4.36B → $5.88B (+$1.52B)

22% more first-time investments, than exits

New positions opened: 33 | Existing positions closed: 27

1.1% more ownership

Funds ownership: 107.69% → 108.79% (+1.1%)

1% more funds holding

Funds holding: 221 → 223 (+2)

0% more funds holding in top 10

Funds holding in top 10: 7 → 7 (0)

Holders
223
Holders Change
+2
Holders Change %
+0.9%
% of All Funds
5.56%
Holding in Top 10
7
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.17%
New
33
Increased
98
Reduced
51
Closed
27
Calls
$37.3M
Puts
$23.2M
Net Calls
+$14.1M
Net Calls Change
+$18.9M

Top Buyers

1
PA
Perceptive Advisors
New York
+$64.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$35.2M
3
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$31.8M
4
Deutsche Bank
Deutsche Bank
Germany
+$31.1M
5
PAMU
Pictet Asset Management (UK)
United Kingdom
+$10.8M

Top Sellers

1
Westfield Capital Management
Westfield Capital Management
Massachusetts
-$53.7M
2
SAM
Senzar Asset Management
New York
-$34.5M
3
HM
HealthCor Management
New York
-$24.4M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$18.8M
5
Point72 Asset Management
Point72 Asset Management
Connecticut
-$16.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
URS
151
Utah Retirement Systems
Utah
$980K – – –
Mirae Asset Global Investments
152
Mirae Asset Global Investments
South Korea
$961K +$827K +15,672 New
AR
153
Advisory Research
Illinois
$918K -$255K -4,830 -24%
Nomura Asset Management
154
Nomura Asset Management
Japan
$895K – – –
DCM
155
Driehaus Capital Management
Illinois
$876K +$755K +14,300 New
SAM
156
Shell Asset Management
Netherlands
$712K – – –
WVP
157
Worth Venture Partners
New Jersey
$702K +$605K +11,469 New
SFM
158
Soros Fund Management
New York
$692K +$338K +6,400 +131%
BCM
159
Basso Capital Management
Connecticut
$680K +$586K +11,100 New
Pacer Advisors
160
Pacer Advisors
Pennsylvania
$652K -$18.2K -345 -3%
GT
161
Glenmede Trust
Pennsylvania
$643K +$523K +9,908 +1,651%
BPGAM
162
BTG Pactual Global Asset Management
Bermuda
$620K -$37.1K -704 -7%
SAMH
163
Shanda Asset Management Holdings
British Virgin Islands
$613K – – –
Canada Life
164
Canada Life
Manitoba, Canada
$608K – – –
OPPM
165
Opus Point Partners Management
New York
$591K +$236K +4,469 +86%
SKK
166
Shepherd Kaplan Krochuk
Massachusetts
$501K – – –
GD
167
Grandfield & Dodd
New York
$466K +$78.1K +1,480 +24%
Teacher Retirement System of Texas
168
Teacher Retirement System of Texas
Texas
$443K +$14.3K +271 +4%
RG
169
Redmile Group
California
$407K – – –
MLICM
170
Metropolitan Life Insurance Company (MetLife)
New York
$404K +$17.7K +336 +5%
FAM
171
Fred Alger Management
New York
$357K +$287K +5,431 +1,378%
VFA
172
Virtus Fund Advisers
Connecticut
$325K -$17.4K -330 -6%
Prudential Financial
173
Prudential Financial
New Jersey
$323K – – –
Fisher Asset Management
174
Fisher Asset Management
Washington
$310K +$267K +5,053 New
Creative Planning
175
Creative Planning
Kansas
$306K -$12.4K -235 -4%
5 6
7
8 9

NBIX Hedge Fund Activity: Q3 2017 in Review

223 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q3 2017, worth a combined $5.88B — up 35% from $4.36B a quarter earlier.

Buyers outnumbered sellers: 33 funds opened new NBIX positions and 27 closed out — a net gain of 6 holders — while 98 added to existing stakes and 51 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $64.1M. The largest seller was Westfield Capital Management, cutting an estimated $53.7M.

  • 223 institutional investors held Neurocrine Biosciences (NBIX) as of Q3 2017, up from 221 in Q2 2017.
  • Funds reported $5.88B of Neurocrine Biosciences stock for Q3 2017, up 35% quarter-over-quarter.
  • 33 funds opened new Neurocrine Biosciences positions in Q3 2017 and 27 closed out, a net change of +6 holders.
  • The largest Neurocrine Biosciences buyer in Q3 2017 was Perceptive Advisors, an estimated $64.1M added.
  • The largest Neurocrine Biosciences seller in Q3 2017 was Westfield Capital Management, an estimated $53.7M sold.

Based on aggregated 13F filings for Q3 2017.